Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
B.1.245	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.59	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.59	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BR.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BR.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BQ.1.7	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BQ.1.7	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CM.5.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CM.5.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBD	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBD	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
EB.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
EB.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBB.1.10	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBB.1.10	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BQ.1.1.61	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BQ.1.1.61	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.2.37	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.2.37	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.2.10	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.2.10	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAS	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XAS	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.3.4	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.3.4	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BE.1.4.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BE.1.4.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CH.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CH.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.2.53	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.2.53	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BL.6	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BL.6	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CM.9	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CM.9	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBB.4.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBB.4.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.576	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.576	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.325	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.325	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.22	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.22	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.521	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.521	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.378	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.378	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.206	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.206	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.28	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used